The objective of this study was to assess the ability of REVITY to reduce topical fungal and yeast in skin and deep partial thickness wound. A pilot study was done, and results were extremely positive as it demonstrated that REVITY can remove these fungal and yeast organisms from infected skin. This advanced study will quantify the pilot study and add statistical significance. Overall, the wounds treated with REVITY (30 and 60 seconds) showed substantially lower fungal counts against both microorganisms (fungus and yeast) for both 20 minute and 24 hours as compared to Lamisil (gold standard drug for topical treatment) and saline controls. Treatment with REVITY for 60 seconds showed superior reduction in fungal counts as compared to those treated with REVITY for 30 seconds. Lamisil control had lower fungal counts when treating wounds infected with either fungus or yeast as compared to Saline control and baseline. The ability of REVITY to demonstrate significant reductions in both fungal and yeast loads in infected skin and deeper tissue may have important clinical implications.



